Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) – Pipeline Review, H1 2019’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders under development targeting Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)

– The report reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Evotec AG

Mateon Therapeutics Inc

Medivir AB

Virobay Inc

Wroclawskie Centrum Badan EIT+ Sp z oo

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Overview

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Companies Involved in Therapeutics Development

Evotec AG

Mateon Therapeutics Inc

Medivir AB

Virobay Inc

Wroclawskie Centrum Badan EIT+ Sp z oo

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Drug Profiles

KGP-207 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIV-711 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-114137 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CTSK for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Dormant Products

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Discontinued Products

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC

3.4.22.38) Product Development Milestones

Featured News & Press Releases

Oct 19, 2018: New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Jul 27, 2018: MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Jun 28, 2018: Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study

Apr 26, 2018: Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27

Nov 09, 2017: MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology

Oct 24, 2017: Medivir Receives FDA Fast Track Designation for MIV-711 for the Treatment of OA

Oct 20, 2017: MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology

Sep 25, 2017: Medivir announces Positive Topline Results from phase IIA osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure

Sep 14, 2017: Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study

Aug 16, 2017: FDA accepts Medivir´s IND application for MIV-711, enabling clinical development in the US

Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"

Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications

Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications

Oct 27, 2016: MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead

Sep 23, 2016: Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Based on Independent Review of Safety Data, and First Patient Enrolled in Extension Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Evotec AG, H1 2019

Pipeline by Mateon Therapeutics Inc, H1 2019

Pipeline by Medivir AB, H1 2019

Pipeline by Virobay Inc, H1 2019

Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2019

Dormant Projects, H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports